| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/22/2005 | CA2125189C Pyropheophorbides and their use in photodynamic therapy |
| 03/22/2005 | CA2103059C Method for making humanized antibodies |
| 03/17/2005 | WO2005024016A1 Mutant hsv vector useful in treating human glioma |
| 03/17/2005 | WO2005023868A1 Serine protease and polynucleotides which encode the serine protease |
| 03/17/2005 | WO2005023817A1 9-amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| 03/17/2005 | WO2005023782A1 Substituted fused pyrimidine-4(3h)-one compound |
| 03/17/2005 | WO2005023771A1 Chemokine receptor antagonist and medical use thereof |
| 03/17/2005 | WO2005023318A1 Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b |
| 03/17/2005 | WO2005023301A1 Remedy and detection drug for bile duct cancer |
| 03/17/2005 | WO2005023300A2 Method for treating, preventing and/or diagnosing cancer, related to the use of mal2 polypeptide |
| 03/17/2005 | WO2005023299A2 Therapeutic human anti-mhc class ii antibodies and their uses |
| 03/17/2005 | WO2005023278A1 A method of extracting glycyrrhizic flavone and the use of glycyrrhizic flavone for preparing anticarcinogen |
| 03/17/2005 | WO2005023276A1 Pharmaceutical active agent against breast cancer |
| 03/17/2005 | WO2005023273A1 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
| 03/17/2005 | WO2005023264A1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
| 03/17/2005 | WO2005023245A1 Novel cycloalkyl’b! condensed indoles |
| 03/17/2005 | WO2005023232A2 Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
| 03/17/2005 | WO2005023230A1 Composition containing nanoparticles containing water-soluble basic drug encapsulated therein |
| 03/17/2005 | WO2005012543A3 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation |
| 03/17/2005 | WO2005004808A3 TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS |
| 03/17/2005 | WO2005003120A3 Metabolites of tricyclic amides useful for inhibition of g-protein function and methods of treatment of proliferative diseases |
| 03/17/2005 | WO2004111008A3 Use of a compound of formula i for making a pharmaceutical composition |
| 03/17/2005 | WO2004098626A8 The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells |
| 03/17/2005 | WO2004098501A3 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
| 03/17/2005 | WO2004094475A3 Tissue factor antibodies and uses thereof |
| 03/17/2005 | WO2004074434A3 Methods and compositions for administering therapeutic and diagnostic agents |
| 03/17/2005 | WO2004072033A3 Pyrazoles and methods of making and using the same |
| 03/17/2005 | WO2004058815A3 Centrosome-associated protein and applications thereof |
| 03/17/2005 | WO2004058759A8 Aryl / hetaryl substituted imidazoquinolines |
| 03/17/2005 | WO2003101425A3 Therapeutic agent-containing polymeric nanoarticles |
| 03/17/2005 | WO2003084305A8 Trihydroxy polyunsaturated eicosanoids |
| 03/17/2005 | WO2003072768A8 Modified human manganese superoxide dismutase and uses thereof |
| 03/17/2005 | WO2003061564A8 Gene expression profiles in liver disease |
| 03/17/2005 | WO2003011898A3 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses |
| 03/17/2005 | WO2002079193A8 Inhibitors of cyclin dependent kinases as anti-cancer agent |
| 03/17/2005 | WO2002050028A8 Substituted benzoindoles as spla2 inhibitors |
| 03/17/2005 | US20050059815 Processes for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom |
| 03/17/2005 | US20050059734 Compositions comprising inhibitors of IMPDH enzyme |
| 03/17/2005 | US20050059729 Substituted cyclic compounds |
| 03/17/2005 | US20050059726 For treating thrombosis and factor xa-related cardiovascular and neurodegenerative diseases; 6-Chloro-N-{(3S)-1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide for example |
| 03/17/2005 | US20050059722 Kinase inhibitors, such as focal adhesion kinase (FAK) inhibitors; treating cancer; 2-methylsulfonyl-N-(3-thiophen-2-yl-1H-indazol-5-yl)benzenesulfonamide for example |
| 03/17/2005 | US20050059714 2-Cyclopropyl-4-(5-fluoro-2-methoxyphenyl)-4-methyl-1-(1H-pyrrolo[2,3-c]pyridin-2-yl)pentan-2-ol; treating diseases of inflammatory, allergic, or proliferative condition; type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumor |
| 03/17/2005 | US20050059712 Immunosuppressants for treating skin disorders, acne, alopecia, estrogen- or androgen-dependent tumors, rheumatoid arthritis, type I and II diabetes, lupus erythematosus, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis, contact dermatitis, graft versus host disease, eczema, asthma |
| 03/17/2005 | US20050059710 Diphenylamino ketone derivatives as MEK inhibitors |
| 03/17/2005 | US20050059686 Pyrrolopyrimidines as phosphodiesterase vII inhibitors |
| 03/17/2005 | US20050059679 Novel hexacyclic compounds |
| 03/17/2005 | US20050059672 tricyclic compounds such as 4-{8-Chloro-6-[[(1-methoxy-cyclopropanecarbonyl)-amino]-(3-methyl-3H-imidazol-4- yl)-methyl]-11H-benzo[5.6]cyclohepta[1,2-b]pyridin-11-yl}-piperazine-1-carboxylic acid isopropyl ester, used as enzyme inhibitors for treatment of cancers |
| 03/17/2005 | US20050059670 Isethionate salt of a selective CKD4 inhibitor |
| 03/17/2005 | US20050059665 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 03/17/2005 | US20050059657 Aminoisoxazole derivatives active as kinase inhibitors |
| 03/17/2005 | US20050059636 For modulation of apoptosis; anticancer agents |
| 03/17/2005 | US20050059625 Immunostimulatory nucleic acid molecules |
| 03/17/2005 | US20050059624 Application of mRNA for use as a therapeutic against tumour diseases |
| 03/17/2005 | US20050059623 linking chaperone protein promoters to genetically engineered genes, then heating |
| 03/17/2005 | US20050059618 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis |
| 03/17/2005 | US20050059616 administering flavonoids and optionally vitamin E or excipients for the prophylaxis of bone or cardiovascular disorders, headaches, hypertension, cancers, leukemia, arteriosclerosis, Alzheimer's disease, inflammatory diseases, rheumatic diseases, acne, alopecia or psoriasis |
| 03/17/2005 | US20050059606 hexapeptides including enantiomers, stereoisomers and tautomers, used as enzyme inhibitors for prophylaxis or prevention of viral diseases |
| 03/17/2005 | US20050059587 Use of a protein for the production of a medicament for stimulating the innate non-specific immune system |
| 03/17/2005 | US20050059116 Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents |
| 03/17/2005 | US20050059113 Antibodies to M-CSF |
| 03/17/2005 | US20050059099 PSCA: prostate stem cell antigen and uses thereof |
| 03/17/2005 | US20050059093 Method for detecting modulators of Notch signalling |
| 03/17/2005 | US20050059081 Dipeptidyl peptidase IV (DPPIV); homology with family of prolyl oligopeptidases; drug screening for enzyme inhibitors for DPPIV which could treat reproductive, inflammatory and metabolic disorders; antibodies for therapeutic or diagnostic use; host cells |
| 03/17/2005 | US20050059067 Using restriction fragment length polymorphism in tyrosine kinase varian t as diagnostic tool in detection of cell proliferative and inflammatory disorders |
| 03/17/2005 | US20050059008 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 03/17/2005 | US20050059005 Microrna molecules |
| 03/17/2005 | US20050058999 Gene involved in apoptosis regulation |
| 03/17/2005 | US20050058722 Mixture of arsenic trioxide and Aloe Vera, Withania Somnifera, Glycine Max, Rubia Cordifolia and/or Acacia Catechu or their extracts; myelodysplastic syndrome, aplastic anemias |
| 03/17/2005 | US20050058668 Allogeneic immunotherapy agent for cancer therapy; vaccine |
| 03/17/2005 | US20050058651 Compositions and methods to prevent metastasis from primary malignancies |
| 03/17/2005 | US20050058644 Compounds for treatment of cancer using lymphocytes, monoclonal antibodies and interferons |
| 03/17/2005 | US20050058639 Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof |
| 03/17/2005 | DE10337863A1 Verwendung von Chromen-4-on-Derivaten The use of chromene-4-one derivatives |
| 03/17/2005 | DE102004040243A1 Transport system for overcoming the blood-brain barrier, useful for the treatment and diagnosis of brain-specific diseases, comprises chitin, chitosan, chitosan oligosaccharides or glucosamine |
| 03/17/2005 | CA2546823A1 9-amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| 03/17/2005 | CA2538372A1 Calixarenes as inhibitors of protein kinase b |
| 03/17/2005 | CA2538141A1 Therapeutic human anti-mhc class ii antibodies and their uses |
| 03/17/2005 | CA2537802A1 Composition containing nanoparticles containing water-soluble basic drug encapsulated therein |
| 03/17/2005 | CA2537677A1 Metal complexes of n-heterocyclic carbenes as radiopharmaceuticals and antibiotics |
| 03/17/2005 | CA2537226A1 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
| 03/17/2005 | CA2537096A1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
| 03/17/2005 | CA2536256A1 Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b |
| 03/17/2005 | CA2535895A1 Anti-cd20 therapy of ocular disorders |
| 03/17/2005 | CA2535762A1 Methods for inhibiting tumor cell proliferation |
| 03/16/2005 | EP1514934A2 Biosynthetic binding protein for cancer marker |
| 03/16/2005 | EP1514929A1 Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
| 03/16/2005 | EP1514877A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process |
| 03/16/2005 | EP1514876A2 Antibody against prostate stem cell antigen (PSCA) |
| 03/16/2005 | EP1514867A2 Substituted phenyl derivatives, their preparation and use |
| 03/16/2005 | EP1514561A1 Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
| 03/16/2005 | EP1514560A1 Process for producing block copolymer/drug composite |
| 03/16/2005 | EP1514558A1 Use of MARKK or MARKK antagonists for the treatment of pathologies characterised by increased or reduced phosphorylation of MARK or tau protein |
| 03/16/2005 | EP1514555A1 Polyherbal formulation for hepatic and splenic disorders |
| 03/16/2005 | EP1514552A1 Novel fused imidazole derivative |
| 03/16/2005 | EP1514116A1 Oxaliplatin anti-resistance agent |
| 03/16/2005 | EP1514115A2 Diagnostic agent, method for detecting a carcinoma, and means for the treatment thereof |
| 03/16/2005 | EP1513942A2 Galactosyl isomalt, method for production and use thereof |
| 03/16/2005 | EP1513880A1 Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation |
| 03/16/2005 | EP1513864A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 03/16/2005 | EP1513863A2 Platinum complexes containing chemically modified bile acids, having antitumor activity |